{
  "pmcid": "PMC10399933",
  "pmid": "37490620",
  "title": "Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants",
  "overall_score": 0.2792266849517112,
  "num_benchmarks": 3,
  "benchmarks": {
    "drug_annotations": {
      "score": 0.0,
      "total_samples": 0,
      "ground_truth_annotations": {
        "count": 0,
        "matched_count": 0,
        "unmatched_count": 0,
        "items": []
      },
      "extra_predictions": {
        "count": 16,
        "items": [
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "simvastatin",
            "annotation": {
              "Variant Annotation ID": 1,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Simvastatin users (n=916). Using statin switching as intolerance: SLCO1B1 c.521C/C vs T/T HR 1.88 (95% CI 1.08\u20133.25), P=0.025. Simvastatin dose \u226540 mg also associated with switching vs 10 mg (HR 1.48, 95% CI 1.03\u20132.12, P=0.035).",
              "Sentence": "Genotype c.521C/C is associated with increased risk of statin switching as a marker of intolerance to simvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance both by using phenotype of switching initial statin to another as a marker of statin intolerance [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, P = 0.025] and statin switching along with creatine kinase measurement (HR 5.44, 95% CI 1.49\u201319.9, P = 0.011).",
                "Of the total 916 simvastatin users, 232 were classified as statin switchers and of those, 22 had a temporally qualifying CK measurement (statin switchers with CK measurement; Fig. [1](#F1)). In the Cox proportional hazards model accounting for the statin dose, SLCO1B1 c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, P = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49\u201319.9, P = 0.011) phenotypes (Table [2](#T2)). Simvastatin dose of 40 mg or higher was also associated with the statin switcher phenotype when compared to 10 mg dose (HR 1.48, 95% 1.03\u20132.12, P = 0.035).",
                "In conclusion, SLCO1B1 c.521T>C genotype was associated with increased switching of simvastatin and pravastatin to other statins in an epidemiological biobank study."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "simvastatin",
                "drug_id": "PA451363",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "simvastatin",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Simvastatin users (n=916). Using statin switching plus temporally qualifying CK measurement as intolerance: SLCO1B1 c.521C/C vs T/T HR 5.44 (95% CI 1.49\u201319.9), P=0.011.",
              "Sentence": "Genotype c.521C/C is associated with increased risk of statin switching with temporally associated CK measurement as a marker of intolerance to simvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of statin switching with temporally associated CK measurement as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Of the total 916 simvastatin users, 232 were classified as statin switchers and of those, 22 had a temporally qualifying CK measurement (statin switchers with CK measurement; Fig. [1](#F1)). In the Cox proportional hazards model accounting for the statin dose, *SLCO1B1* c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, *P* = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49\u201319.9, *P* = 0.011) phenotypes (Table [2](#T2)).",
                "In a large observational cohort of statin initiators, we replicated the well-characterized association of *SLCO1B1* c.521T>C with simvastatin intolerance. The effect was consistent in both of our intolerance phenotypes, the first based on statin switching only and the second based on statin switching and temporally associated CK measurement."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "simvastatin",
                "drug_id": "PA451363",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "simvastatin",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Simvastatin users. For statin switching phenotype, SLCO1B1 c.521T/C vs T/T HR 0.94 (95% CI 0.70\u20131.24), P=0.640, indicating no significant association with intolerance.",
              "Sentence": "Genotype c.521T/C is not associated with risk of statin switching as a marker of intolerance to simvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "In the Cox proportional hazards model accounting for the statin dose, SLCO1B1 c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, P = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49\u201319.9, P = 0.011) phenotypes (Table 2).",
                "Table 2 Caption: Associations of SLCO1B1 c.521T>C single nucleotide variation with intolerance to simvastatin",
                "c.521T/T | 584 | 146 |   |   | 10 |   |   |\nc.521T/C | 300 | 72 | 0.94 (0.70\u20131.24) | 0.640 | 9 | 1.75 (0.71\u20134.31) | 0.226 |\nc.521C/C | 32 | 14 | 1.88 (1.08\u20133.25) | 0.025 | 3 | 5.44 (1.49\u201319.9) | 0.011"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "simvastatin",
                "drug_id": "PA451363",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "simvastatin",
            "annotation": {
              "Variant Annotation ID": 4,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Simvastatin users. For statin switching + CK phenotype, SLCO1B1 c.521T/C vs T/T HR 1.75 (95% CI 0.71\u20134.31), P=0.226, indicating no significant association.",
              "Sentence": "Genotype c.521T/C is not associated with risk of statin switching with temporally associated CK measurement as a marker of intolerance to simvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching with temporally associated CK measurement as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "In the Cox proportional hazards model accounting for the statin dose, *SLCO1B1* c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, *P* = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49\u201319.9, *P* = 0.011) phenotypes (Table [2](#T2)).",
                "Table 2 Caption: Associations of SLCO1B1 c.521T>C single nucleotide variation with intolerance to simvastatin",
                "| c.521T/T | 584 | 146 |   |   | 10 |   |   |\n| c.521T/C | 300 | 72 | 0.94 (0.70\u20131.24) | 0.640 | 9 | 1.75 (0.71\u20134.31) | 0.226 |\n| c.521C/C | 32 | 14 | 1.88 (1.08\u20133.25) | 0.025 | 3 | 5.44 (1.49\u201319.9) | 0.011 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "simvastatin",
                "drug_id": "PA451363",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "atorvastatin",
            "annotation": {
              "Variant Annotation ID": 5,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "atorvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Atorvastatin users (n=780). For statin switching phenotype: c.521T/C vs T/T HR 0.82 (95% CI 0.55\u20131.23), P=0.339; c.521C/C vs T/T HR 1.13 (95% CI 0.52\u20132.44), P=0.759. Authors state: 'Neither the SLCO1B1 or ABCG2 genotypes ... were associated with the statin intolerance phenotypes.'",
              "Sentence": "Genotypes c.521T/C or c.521C/C are not associated with risk of statin switching as a marker of intolerance to atorvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C or c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Atorvastatin had median follow-up time of 556.5 days. There were 780 atorvastatin users. Of those, 128 were categorized as statin switchers and 18 had a temporally qualifying CK measurement. Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes (Table [3](#T3)).",
                "Table 3. Associations of SLCO1B1 c.521T>C and ABCG2 c.421C>A single nucleotide variations with intolerance to atorvastatin\n...\nSLCO1B1\n...\nc.521T/T | 506 | 88 |   |   | 11 |   |   |\nc.521T/C | 238 | 33 | 0.82 (0.55\u20131.23) | 0.339 | 6 | 1.25 (0.46\u20133.38) | 0.667 |\nc.521C/C | 36 | 7 | 1.13 (0.52\u20132.44) | 0.759 | 1 | 1.30 (0.17\u201310.1) | 0.799 |",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes. For atorvastatin, no signals were evident for genotype-driven increased risk in our cohort of 780 atorvastatin users who most often had 10 and 20 mg prescribed as a starting dose."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "atorvastatin",
                "drug_id": "PA448500",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "atorvastatin",
            "annotation": {
              "Variant Annotation ID": 6,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "atorvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Atorvastatin users. For statin switching + CK phenotype: c.521T/C vs T/T HR 1.25 (95% CI 0.46\u20133.38), P=0.667; c.521C/C vs T/T HR 1.30 (95% CI 0.17\u201310.1), P=0.799. No significant associations.",
              "Sentence": "Genotypes c.521T/C or c.521C/C are not associated with risk of statin switching with temporally associated CK measurement as a marker of intolerance to atorvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C or c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching with temporally associated CK measurement as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Atorvastatin had median follow-up time of 556.5 days. There were 780 atorvastatin users. Of those, 128 were categorized as statin switchers and 18 had a temporally qualifying CK measurement. Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes (Table [3](#T3)).",
                "Table 3 Caption: Associations of SLCO1B1 c.521T>C and ABCG2 c.421C>A single nucleotide variations with intolerance to atorvastatin",
                "| c.521T/T | 506 | 88 |   |   | 11 |   |   |\n| c.521T/C | 238 | 33 | 0.82 (0.55\u20131.23) | 0.339 | 6 | 1.25 (0.46\u20133.38) | 0.667 |\n| c.521C/C | 36 | 7 | 1.13 (0.52\u20132.44) | 0.759 | 1 | 1.30 (0.17\u201310.1) | 0.799 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "atorvastatin",
                "drug_id": "PA448500",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2231142",
            "gene": "ABCG2",
            "drug": "atorvastatin",
            "annotation": {
              "Variant Annotation ID": 7,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "atorvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Atorvastatin users. For statin switching phenotype: ABCG2 c.421C/A or A/A vs C/C HR 1.04 (95% CI 0.63\u20131.71), P=0.877. Authors: 'Neither the SLCO1B1 or ABCG2 genotypes ... were associated with the statin intolerance phenotypes.'",
              "Sentence": "Genotypes c.421C/A or c.421A/A are not associated with risk of statin switching as a marker of intolerance to atorvastatin in patients with hypercholesterolemia as compared to genotype c.421C/C.",
              "Alleles": "c.421C/A or c.421A/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.421C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Atorvastatin had median follow-up time of 556.5 days. There were 780 atorvastatin users. Of those, 128 were categorized as statin switchers and 18 had a temporally qualifying CK measurement. Neither the SLCO1B1 or ABCG2 genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes (Table [3](#T3)).",
                "ABCG2\n...\n| c.421C/C | 675 | 110 |   |   | 15 |   |   |\n| c.421C/A or A/A | 105 | 18 | 1.04 (0.63\u20131.71) | 0.877 | 3 | 1.27 (0.37\u20134.39) | 0.706 |",
                "Table 3 Caption: Associations of SLCO1B1 c.521T>C and ABCG2 c.421C>A single nucleotide variations with intolerance to atorvastatin"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2231142",
                "variant_id": "PA166156544",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "atorvastatin",
                "drug_id": "PA448500",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2231142",
            "gene": "ABCG2",
            "drug": "atorvastatin",
            "annotation": {
              "Variant Annotation ID": 8,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "atorvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Atorvastatin users. For statin switching + CK phenotype: ABCG2 c.421C/A or A/A vs C/C HR 1.27 (95% CI 0.37\u20134.39), P=0.706. No significant association.",
              "Sentence": "Genotypes c.421C/A or c.421A/A are not associated with risk of statin switching with temporally associated CK measurement as a marker of intolerance to atorvastatin in patients with hypercholesterolemia as compared to genotype c.421C/C.",
              "Alleles": "c.421C/A or c.421A/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching with temporally associated CK measurement as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.421C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Atorvastatin had median follow-up time of 556.5 days. There were 780 atorvastatin users. Of those, 128 were categorized as statin switchers and 18 had a temporally qualifying CK measurement. Neither the *SLCO1B1* or *ABCG2* genotypes nor atorvastatin dose were associated with the statin intolerance phenotypes (Table [3](#T3)).\"",
                "Table 3 (ABCG2 section): \"c.421C/C | 675 | 110 |   |   | 15 |   |   |\n| c.421C/A or A/A | 105 | 18 | 1.04 (0.63\u20131.71) | 0.877 | 3 | 1.27 (0.37\u20134.39) | 0.706 |\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2231142",
                "variant_id": "PA166156544",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "atorvastatin",
                "drug_id": "PA448500",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "rosuvastatin",
            "annotation": {
              "Variant Annotation ID": 9,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Rosuvastatin users (n=184). For statin switching phenotype: c.521T/C or C/C vs T/T HR 0.67 (95% CI 0.32\u20131.43), P=0.301. Authors: 'the SLCO1B1 or ABCG2 genotypes were not associated with statin intolerance.'",
              "Sentence": "Genotypes c.521T/C or c.521C/C are not associated with risk of statin switching as a marker of intolerance to rosuvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C or c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Rosuvastatin median follow-up time was 92.5 days. Rosuvastatin had total of 184 users of whom 32 were categorized as statin switchers. Rosuvastatin dose of 10 mg was associated with increased risk of statin intolerance when compared to 5 mg dose, but the *SLCO1B1* or *ABCG2* genotypes were not associated with statin intolerance (Table [4](#T4)).",
                "Table 4. ... c.521T/T | 119 | 22 |   |   |\n| c.521T/C or C/C | 65 | 10 | 0.67 (0.32\u20131.43) | 0.301 |",
                "We observed no statistically significant increase in statin intolerance risk for atorvastatin, fluvastatin or rosuvastatin with the studied genotypes. ... The rosuvastatin cohort consisted of only 184 patients who had most often 5 or 10 mg prescribed starting dose with no tendencies for increased risk in carriers of the candidate risk alleles."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "rosuvastatin",
                "drug_id": "PA134308647",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2231142",
            "gene": "ABCG2",
            "drug": "rosuvastatin",
            "annotation": {
              "Variant Annotation ID": 10,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Rosuvastatin users. For statin switching phenotype: ABCG2 c.421C/A or A/A vs C/C HR 0.81 (95% CI 0.31\u20132.10), P=0.660. No significant association with intolerance.",
              "Sentence": "Genotypes c.421C/A or c.421A/A are not associated with risk of statin switching as a marker of intolerance to rosuvastatin in patients with hypercholesterolemia as compared to genotype c.421C/C.",
              "Alleles": "c.421C/A or c.421A/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.421C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "\"Rosuvastatin median follow-up time was 92.5 days. Rosuvastatin had total of 184 users of whom 32 were categorized as statin switchers. Rosuvastatin dose of 10 mg was associated with increased risk of statin intolerance when compared to 5 mg dose, but the *SLCO1B1* or *ABCG2* genotypes were not associated with statin intolerance (Table [4](#T4)).\"",
                "Table 4 (Rosuvastatin): \"ABCG2 ... c.421C/C | 153 | 27 |   |   | c.421C/A or A/A | 31 | 5 | 0.81 (0.31\u20132.10) | 0.660\"",
                "\"The rosuvastatin cohort consisted of only 184 patients who had most often 5 or 10 mg prescribed starting dose with no tendencies for increased risk in carriers of the candidate risk alleles.\""
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2231142",
                "variant_id": "PA166156544",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "rosuvastatin",
                "drug_id": "PA134308647",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "fluvastatin",
            "annotation": {
              "Variant Annotation ID": 11,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Fluvastatin users (n=70). Statin switching phenotype: c.521T/C or C/C vs T/T HR 1.42 (95% CI 0.67\u20133.01), P=0.36. Authors: 'No statistically significant association was found for fluvastatin.'",
              "Sentence": "Genotypes c.521T/C or c.521C/C are not associated with risk of statin switching as a marker of intolerance to fluvastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C or c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Fluvastatin had 70 users of whom 31 were categorized as statin switchers. No statistically significant association was found for fluvastatin (Table [5](#T5)).",
                "Table 5 Caption: Associations of SLCO1B1 c.521T>C and ABCG2 c.421C>A single nucleotide variations, as well as CYP2C9 phenotypes with intolerance to fluvastatin",
                "| c.521T/T | 39 | 15 |   |   |\n| c.521T/C or C/C | 31 | 16 | 1.42 (0.67\u20133.01) | 0.36 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "fluvastatin",
                "drug_id": "PA449688",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "rs2231142",
            "gene": "ABCG2",
            "drug": "fluvastatin",
            "annotation": {
              "Variant Annotation ID": 12,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Fluvastatin users. Statin switching phenotype: ABCG2 c.421C/A or A/A vs C/C HR 2.06 (95% CI 0.84\u20135.05), P=0.113. Trend but not statistically significant.",
              "Sentence": "Genotypes c.421C/A or c.421A/A are not associated with risk of statin switching as a marker of intolerance to fluvastatin in patients with hypercholesterolemia as compared to genotype c.421C/C.",
              "Alleles": "c.421C/A or c.421A/A",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.421C/C",
              "Comparison Metabolizer types": null,
              "Citations": [
                "Fluvastatin had 70 users of whom 31 were categorized as statin switchers. No statistically significant association was found for fluvastatin (Table [5](#T5)).",
                "| ABCG2 |  |  |  |  |\n| 20 mg dose | 19 | 7 |   |   |\n| 40 mg dose | 14 | 6 | 0.88 (0.30\u20132.64) | 0.825 |\n| 80 mg dose | 37 | 18 | 1.39 (0.58\u20133.34) | 0.466 |\n| c.421C/C | 61 | 25 |   |   |\n| c.421C/A or A/A | 9 | 6 | 2.06 (0.84\u20135.05) | 0.113 |"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs2231142",
                "variant_id": "PA166156544",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "fluvastatin",
                "drug_id": "PA449688",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "CYP2C9*1",
            "gene": "CYP2C9",
            "drug": "fluvastatin",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "CYP2C9*1",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Fluvastatin users. CYP2C9 poor or intermediate metabolizers (homozygous or compound heterozygous *2 or *3, or heterozygotes) vs normal metabolizers: HR 1.36 (95% CI 0.67\u20132.78), P=0.394 for statin switching phenotype. No statistically significant association.",
              "Sentence": "CYP2C9 poor or intermediate metabolizers are not associated with increased risk of statin switching as a marker of intolerance to fluvastatin in patients with hypercholesterolemia as compared to CYP2C9 normal metabolizers.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer or intermediate metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Fluvastatin had 70 users of whom 31 were categorized as statin switchers. No statistically significant association was found for fluvastatin (Table [5](#T5)).",
                "| CYP2C9 |  |  |  |  |\n| 20 mg dose | 19 | 7 |   |   |\n| 40 mg dose | 14 | 6 | 0.89 (0.30\u20132.65) | 0.832 |\n| 80 mg dose | 37 | 18 | 1.39 (0.58\u20133.34) | 0.465 |\n| NM | 45 | 14 |   |   |\n| PM or IM | 25 | 17 | 1.36 (0.67\u20132.78) | 0.394 |",
                "For fluvastatin, there was a trend towards increased risk of statin intolerance with a point estimate of HR at 1.88 in carriers of 2\u20134 risk alleles, but perhaps due to low sample size, the finding was not statistically significant."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "fluvastatin",
                "drug_id": "PA449688",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C9*2",
            "gene": "CYP2C9",
            "drug": "fluvastatin",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "CYP2C9*2",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Fluvastatin users. CYP2C9 poor or intermediate metabolizers (homozygous or compound heterozygous *2 or *3, or heterozygotes) vs normal metabolizers: HR 1.36 (95% CI 0.67\u20132.78), P=0.394 for statin switching phenotype. No statistically significant association.",
              "Sentence": "CYP2C9 poor or intermediate metabolizers are not associated with increased risk of statin switching as a marker of intolerance to fluvastatin in patients with hypercholesterolemia as compared to CYP2C9 normal metabolizers.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer or intermediate metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Fluvastatin had 70 users of whom 31 were categorized as statin switchers. No statistically significant association was found for fluvastatin (Table [5](#T5)).",
                "| CYP2C9 |  |  |  |  |\n| 20 mg dose | 19 | 7 |   |   |\n| 40 mg dose | 14 | 6 | 0.89 (0.30\u20132.65) | 0.832 |\n| 80 mg dose | 37 | 18 | 1.39 (0.58\u20133.34) | 0.465 |\n| NM | 45 | 14 |   |   |\n| PM or IM | 25 | 17 | 1.36 (0.67\u20132.78) | 0.394 |",
                "For fluvastatin, there was a trend towards increased risk of statin intolerance with a point estimate of HR at 1.88 in carriers of 2\u20134 risk alleles, but perhaps due to low sample size, the finding was not statistically significant."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "fluvastatin",
                "drug_id": "PA449688",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "CYP2C9*3",
            "gene": "CYP2C9",
            "drug": "fluvastatin",
            "annotation": {
              "Variant Annotation ID": 13,
              "Variant/Haplotypes": "CYP2C9*3",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "no",
              "Notes": "Fluvastatin users. CYP2C9 poor or intermediate metabolizers (homozygous or compound heterozygous *2 or *3, or heterozygotes) vs normal metabolizers: HR 1.36 (95% CI 0.67\u20132.78), P=0.394 for statin switching phenotype. No statistically significant association.",
              "Sentence": "CYP2C9 poor or intermediate metabolizers are not associated with increased risk of statin switching as a marker of intolerance to fluvastatin in patients with hypercholesterolemia as compared to CYP2C9 normal metabolizers.",
              "Alleles": null,
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer or intermediate metabolizer",
              "isPlural": "Are",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": null,
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": null,
              "Comparison Metabolizer types": "normal metabolizer",
              "Citations": [
                "Fluvastatin had 70 users of whom 31 were categorized as statin switchers. No statistically significant association was found for fluvastatin (Table [5](#T5)).",
                "| CYP2C9 |  |  |  |  |\n| 20 mg dose | 19 | 7 |   |   |\n| 40 mg dose | 14 | 6 | 0.89 (0.30\u20132.65) | 0.832 |\n| 80 mg dose | 37 | 18 | 1.39 (0.58\u20133.34) | 0.465 |\n| NM | 45 | 14 |   |   |\n| PM or IM | 25 | 17 | 1.36 (0.67\u20132.78) | 0.394 |",
                "For fluvastatin, there was a trend towards increased risk of statin intolerance with a point estimate of HR at 1.88 in carriers of 2\u20134 risk alleles, but perhaps due to low sample size, the finding was not statistically significant."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "CYP2C9*1, CYP2C9*2, CYP2C9*3",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "fluvastatin",
                "drug_id": "PA449688",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "rs4149056",
            "gene": "SLCO1B1",
            "drug": "pravastatin",
            "annotation": {
              "Variant Annotation ID": 14,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "PMID": 37490620,
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "Pravastatin users (n=92). Statin switching phenotype: SLCO1B1 c.521T/C or C/C vs T/T HR 2.11 (95% CI 1.01\u20134.39), P=0.047. Authors: 'SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype.'",
              "Sentence": "Genotypes c.521T/C or c.521C/C are associated with increased risk of statin switching as a marker of intolerance to pravastatin in patients with hypercholesterolemia as compared to genotype c.521T/T.",
              "Alleles": "c.521T/C or c.521C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Are",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "PD/PK terms": "risk of statin switching as a marker of intolerance to",
              "Multiple drugs And/or": null,
              "Population types": "in patients with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "Citations": [
                "The sample sizes for fluvastatin and pravastatin were relatively small, but *SLCO1B1* c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, *P* = 0.047).",
                "Pravastatin had a total of 92 users of which 29 were categorized as statin switchers. *SLCO1B1* c.521T/C or C/C genotype was associated with an increased risk of pravastatin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, *P* = 0.047; Table [6](#T6)).",
                "In addition to simvastatin, we observed that heterozygous or homozygous *SLCO1B1* c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "rs4149056",
                "variant_id": "PA166154579",
                "confidence": 1.0
              },
              "Drug(s)_normalized": {
                "normalized": "pravastatin",
                "drug_id": "PA451089",
                "confidence": 1.0
              }
            }
          }
        ]
      }
    },
    "phenotype_annotations": {
      "score": 0.25092503463938115,
      "total_samples": 7,
      "ground_truth_annotations": {
        "count": 7,
        "matched_count": 2,
        "unmatched_count": 5,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8685351431369781,
            "annotation": {
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "Phenotype Category": "Toxicity",
              "Alleles": "CC",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Discontinuation",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "TT"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "c.521C/C",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "simvastatin",
                "prediction": "simvastatin",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CC",
                "prediction": "C/C",
                "score": 0.9050132036209106,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance (switch to another statin)",
                "score": 0.9133453965187073,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "c.521T/T",
                "score": 0.8669928312301636,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8668882131576539,
            "annotation": {
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "Phenotype Category": "Toxicity",
              "Alleles": "CC + CT",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Phenotype": "Side Effect:Discontinuation",
              "When treated with/exposed to/when assayed with": "when treated with",
              "Comparison Allele(s) or Genotype(s)": "TT"
            },
            "field_comparison": {
              "Variant/Haplotypes": {
                "ground_truth": "rs4149056",
                "prediction": "c.521T/C",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Gene": {
                "ground_truth": "SLCO1B1",
                "prediction": "SLCO1B1",
                "score": 1.0,
                "match_status": "match"
              },
              "Drug(s)": {
                "ground_truth": "pravastatin",
                "prediction": "pravastatin",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype Category": {
                "ground_truth": "Toxicity",
                "prediction": "toxicity",
                "score": 1.0,
                "match_status": "match"
              },
              "Alleles": {
                "ground_truth": "CC + CT",
                "prediction": "T/C or C/C",
                "score": 0.8885439038276672,
                "match_status": "partial_match"
              },
              "Is/Is Not associated": {
                "ground_truth": "Associated with",
                "prediction": "Associated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Direction of effect": {
                "ground_truth": "increased",
                "prediction": "increased",
                "score": 1.0,
                "match_status": "match"
              },
              "Phenotype": {
                "ground_truth": "Side Effect:Discontinuation",
                "prediction": "Side Effect:Statin intolerance (switch to another statin)",
                "score": 0.9133453965187073,
                "match_status": "partial_match"
              },
              "When treated with/exposed to/when assayed with": {
                "ground_truth": "when treated with",
                "prediction": "when treated with",
                "score": 1.0,
                "match_status": "match"
              },
              "Comparison Allele(s) or Genotype(s)": {
                "ground_truth": "TT",
                "prediction": "c.521T/T",
                "score": 0.8669928312301636,
                "match_status": "partial_match"
              }
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*1",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*2",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452196120,
              "Variant/Haplotypes": "CYP2C9*3",
              "Gene": "CYP2C9",
              "Drug(s)": "fluvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "CYP2C9 *2/*2 + *2/*3 + *3/*3 (assigned as poor metabolizer phenotype) is not associated with increased risk of discontinuation when treated with fluvastatin as compared to CYP2C9 *1/*1 + *1/*2 + *1/*3 (assigned as intermediate metabolizer and normal metabolizer phenotype) .",
              "Alleles": "*2/*2 + *2/*3 + *3/*3",
              "Specialty Population": null,
              "Metabolizer types": "poor metabolizer",
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "*1/*1 + *1/*2 + *1/*3",
              "Comparison Metabolizer types": "normal metabolizer and intermediate metabolizer",
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196120",
              "_expanded_from_multi_variant": true
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452196040,
              "Variant/Haplotypes": "rs4149056",
              "Gene": "SLCO1B1",
              "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin",
              "Sentence": "Genotypes CC + CT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype TT.",
              "Alleles": "CC + CT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "or",
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "TT",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196040"
            }
          },
          {
            "matched": false,
            "annotation": {
              "Variant Annotation ID": 1452196080,
              "Variant/Haplotypes": "rs2231142",
              "Gene": "ABCG2",
              "Drug(s)": "atorvastatin, fluvastatin, rosuvastatin",
              "PMID": 37490620,
              "Phenotype Category": "Toxicity",
              "Significance": "no",
              "Notes": "effect is described as \"Statin switch\" as measured by changes in prescription refills in the medical record, and attributed to muscle side effects (therefore tagged as toxicity). \"No significant association was observed with atorvastatin and rosuvastatin.\" \"The sample sizes for fluvastatin and pravastatin were relatively small\"\"No statistically significant association was found for fluvastatin\" Alleles complemented to plus chromosomal strand.",
              "Sentence": "Genotypes GT + TT is not associated with increased risk of discontinuation when treated with atorvastatin, fluvastatin or rosuvastatin as compared to genotype GG.",
              "Alleles": "GT + TT",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Not associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Discontinuation",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": "or",
              "Population types": null,
              "Population Phenotypes or diseases": null,
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "GG",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "1452196080"
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 3,
        "items": [
          {
            "variant": "c.521C/C",
            "gene": "SLCO1B1",
            "drug": "simvastatin",
            "annotation": {
              "Variant Annotation ID": 2,
              "Variant/Haplotypes": "c.521C/C",
              "Gene": "SLCO1B1",
              "Drug(s)": "simvastatin",
              "PMID": "37490620",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "SLCO1B1 c.521C/C genotype was associated with increased risk of simvastatin intolerance defined as statin switching plus temporally related CK measurement (HR 5.44, 95% CI 1.49\u201319.9, P=0.011) compared with c.521T/T.",
              "Sentence": "c.521C/C is associated with increased risk of Statin intolerance (switch plus CK measurement) when treated with simvastatin in people with Hypercholesterolemia.",
              "Alleles": "C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Statin intolerance (switch plus CK measurement)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "2",
              "Citations": [
                "We confirmed the association of SLCO1B1 c.521C/C genotype with simvastatin intolerance both by using phenotype of switching initial statin to another as a marker of statin intolerance [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, P = 0.025] and statin switching along with creatine kinase measurement (HR 5.44, 95% CI 1.49\u201319.9, P = 0.011).",
                "In the Cox proportional hazards model accounting for the statin dose, SLCO1B1 c.521C/C genotype was associated with an increased risk of simvastatin intolerance when compared to homozygous reference T/T genotype using both statin switcher [hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.08\u20133.25, P = 0.025] and statin switcher with CK measurement (HR 5.44, 95% CI 1.49\u201319.9, P = 0.011) phenotypes (Table [2](#T2)).",
                "In conclusion, SLCO1B1 c.521T>C genotype was associated with increased switching of simvastatin and pravastatin to other statins in an epidemiological biobank study."
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "c.521C/C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "simvastatin",
                "drug_id": "PA451363",
                "confidence": 1.0
              }
            }
          },
          {
            "variant": "or",
            "gene": "SLCO1B1",
            "drug": "pravastatin",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "or",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "PMID": "37490620",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "SLCO1B1 c.521T/C or C/C genotype was associated with increased risk of pravastatin intolerance defined by statin switching when compared to c.521T/T (HR 2.11, 95% CI 1.01\u20134.39, P=0.047).",
              "Sentence": "c.521T/C or C/C is associated with increased risk of Statin intolerance (switch to another statin) when treated with pravastatin in people with Hypercholesterolemia.",
              "Alleles": "T/C or C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Statin intolerance (switch to another statin)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "\u201cThe sample sizes for fluvastatin and pravastatin were relatively small, but SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047).\u201d",
                "\u201cPravastatin had a total of 92 users of which 29 were categorized as statin switchers. SLCO1B1 c.521T/C or C/C genotype was associated with an increased risk of pravastatin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047; Table [6]).\u201d",
                "\u201cIn addition to simvastatin, we observed that heterozygous or homozygous SLCO1B1 c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "c.521T/C or C/C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "pravastatin",
                "drug_id": "PA451089",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          },
          {
            "variant": "C/C",
            "gene": "SLCO1B1",
            "drug": "pravastatin",
            "annotation": {
              "Variant Annotation ID": 3,
              "Variant/Haplotypes": "C/C",
              "Gene": "SLCO1B1",
              "Drug(s)": "pravastatin",
              "PMID": "37490620",
              "Phenotype Category": "toxicity",
              "Significance": "yes",
              "Notes": "SLCO1B1 c.521T/C or C/C genotype was associated with increased risk of pravastatin intolerance defined by statin switching when compared to c.521T/T (HR 2.11, 95% CI 1.01\u20134.39, P=0.047).",
              "Sentence": "c.521T/C or C/C is associated with increased risk of Statin intolerance (switch to another statin) when treated with pravastatin in people with Hypercholesterolemia.",
              "Alleles": "T/C or C/C",
              "Specialty Population": null,
              "Metabolizer types": null,
              "isPlural": "Is",
              "Is/Is Not associated": "Associated with",
              "Direction of effect": "increased",
              "Side effect/efficacy/other": "risk of",
              "Phenotype": "Side Effect:Statin intolerance (switch to another statin)",
              "Multiple phenotypes And/or": null,
              "When treated with/exposed to/when assayed with": "when treated with",
              "Multiple drugs And/or": null,
              "Population types": "in people with",
              "Population Phenotypes or diseases": "Disease:Hypercholesterolemia",
              "Multiple phenotypes or diseases And/or": null,
              "Comparison Allele(s) or Genotype(s)": "c.521T/T",
              "Comparison Metabolizer types": null,
              "PMID_norm": "37490620",
              "Variant Annotation ID_norm": "3",
              "Citations": [
                "\u201cThe sample sizes for fluvastatin and pravastatin were relatively small, but SLCO1B1 c.521T>C carriers had an increased risk of pravastatin intolerance defined by statin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047).\u201d",
                "\u201cPravastatin had a total of 92 users of which 29 were categorized as statin switchers. SLCO1B1 c.521T/C or C/C genotype was associated with an increased risk of pravastatin switching when compared to homozygous reference T/T genotype (HR 2.11, 95% CI 1.01\u20134.39, P = 0.047; Table [6]).\u201d",
                "\u201cIn addition to simvastatin, we observed that heterozygous or homozygous SLCO1B1 c.521T>C carriers had a higher risk of pravastatin intolerance based on statin switching phenotype when compared to reference allele homozygotes.\u201d"
              ],
              "Variant/Haplotypes_normalized": {
                "normalized": "c.521T/C or C/C",
                "variant_id": null,
                "confidence": 0.0
              },
              "Drug(s)_normalized": {
                "normalized": "pravastatin",
                "drug_id": "PA451089",
                "confidence": 1.0
              },
              "_expanded_from_multi_variant": true
            }
          }
        ]
      }
    },
    "study_parameters": {
      "score": 0.7405191878477733,
      "total_samples": 10,
      "ground_truth_annotations": {
        "count": 10,
        "matched_count": 10,
        "unmatched_count": 0,
        "items": [
          {
            "matched": true,
            "overall_match_score": 0.8174077798338497,
            "annotation": {
              "Study Parameters ID": 1452195945,
              "Variant Annotation ID": 1452195940,
              "Study Type": null,
              "Study Cases": 916.0,
              "Study Controls": null,
              "Characteristics": "Statin switch",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.025",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.88,
              "Confidence Interval Start": 1.08,
              "Confidence Interval Stop": 3.25,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452195945,
                "prediction": 2,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195940,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 916.0,
                "prediction": 916,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Finnish simvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.8959322571754456,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.025",
                "prediction": "= 0.025",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 1.88,
                "prediction": 1.88,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.08,
                "prediction": 1.08,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 3.25,
                "prediction": 3.25,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8170601900886086,
            "annotation": {
              "Study Parameters ID": 1452195946,
              "Variant Annotation ID": 1452195940,
              "Study Type": null,
              "Study Cases": 916.0,
              "Study Controls": null,
              "Characteristics": "Statin switch",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.011",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 5.44,
              "Confidence Interval Start": 1.49,
              "Confidence Interval Stop": 19.9,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452195946,
                "prediction": 4,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195940,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 916.0,
                "prediction": 916,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Finnish simvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of SLCO1B1 c.521C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.8900232315063477,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.011",
                "prediction": "= 0.011",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 5.44,
                "prediction": 5.44,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.49,
                "prediction": 1.49,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 19.9,
                "prediction": 19.9,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.8168740132275749,
            "annotation": {
              "Study Parameters ID": 1452195960,
              "Variant Annotation ID": 1452195947,
              "Study Type": null,
              "Study Cases": 92.0,
              "Study Controls": null,
              "Characteristics": "Statin switch",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.047",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 2.11,
              "Confidence Interval Start": 1.01,
              "Confidence Interval Stop": 4.39,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452195960,
                "prediction": 50,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452195947,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 92.0,
                "prediction": 92,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch",
                "prediction": "Finnish pravastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521T/C or C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.8868582248687744,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.047",
                "prediction": "= 0.047",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "HR",
                "prediction": "HR",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat": {
                "ground_truth": 2.11,
                "prediction": 2.11,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Start": {
                "ground_truth": 1.01,
                "prediction": 1.01,
                "score": 1.0,
                "match_status": "match"
              },
              "Confidence Interval Stop": {
                "ground_truth": 4.39,
                "prediction": 4.39,
                "score": 1.0,
                "match_status": "match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5835839615148657,
            "annotation": {
              "Study Parameters ID": 1452196101,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 780.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, atorvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.877",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196101,
                "prediction": 13,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 780.0,
                "prediction": 780,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, atorvastatin",
                "prediction": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of ABCG2 c.421C/A or A/A vs c.421C/C, dose-adjusted Cox model",
                "score": 0.9209273457527161,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.877",
                "prediction": "= 0.877",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.04,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.63,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 1.71,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5835747964241925,
            "annotation": {
              "Study Parameters ID": 1452196060,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 780.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, atorvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.759",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196060,
                "prediction": 10,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 780.0,
                "prediction": 780,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, atorvastatin",
                "prediction": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.9207715392112732,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.759",
                "prediction": "= 0.759",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.13,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.52,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.44,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5832647085189819,
            "annotation": {
              "Study Parameters ID": 1452196045,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.36",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196045,
                "prediction": 38,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 70,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521T/C or C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.9155000448226929,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.36",
                "prediction": "= 0.360",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.42,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 3.01,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5832131645258736,
            "annotation": {
              "Study Parameters ID": 1452196085,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.113",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196085,
                "prediction": 39,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 70,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of ABCG2 c.421C/A or A/A vs c.421C/C, dose-adjusted Cox model",
                "score": 0.9146237969398499,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.113",
                "prediction": "= 0.113",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 2.06,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.84,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 5.05,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5832123721347136,
            "annotation": {
              "Study Parameters ID": 1452196130,
              "Variant Annotation ID": 1452196120,
              "Study Type": null,
              "Study Cases": 70.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, fluvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.394",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196130,
                "prediction": 40,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196120,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 70.0,
                "prediction": 70,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, fluvastatin",
                "prediction": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of CYP2C9 poor or intermediate metabolizers vs normal metabolizers, dose-adjusted Cox model",
                "score": 0.9146103262901306,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.394",
                "prediction": "= 0.394",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 1.36,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.78,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5829927290187162,
            "annotation": {
              "Study Parameters ID": 1452196046,
              "Variant Annotation ID": 1452196040,
              "Study Type": null,
              "Study Cases": 184.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, rosuvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.301",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196046,
                "prediction": 29,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196040,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 184.0,
                "prediction": 184,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, rosuvastatin",
                "prediction": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521T/C or C/C vs c.521T/T, dose-adjusted Cox model",
                "score": 0.9108763933181763,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.301",
                "prediction": "= 0.301",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.67,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.32,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 1.43,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          },
          {
            "matched": true,
            "overall_match_score": 0.5828091186635634,
            "annotation": {
              "Study Parameters ID": 1452196100,
              "Variant Annotation ID": 1452196080,
              "Study Type": null,
              "Study Cases": 184.0,
              "Study Controls": null,
              "Characteristics": "Statin switch, rosuvastatin",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.660",
              "Ratio Stat Type": "Unknown",
              "Ratio Stat": null,
              "Confidence Interval Start": null,
              "Confidence Interval Stop": null,
              "Biogeographical Groups": "European"
            },
            "field_comparison": {
              "Study Parameters ID": {
                "ground_truth": 1452196100,
                "prediction": 30,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Variant Annotation ID": {
                "ground_truth": 1452196080,
                "prediction": null,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Type": {
                "ground_truth": null,
                "prediction": "cohort",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Study Cases": {
                "ground_truth": 184.0,
                "prediction": 184,
                "score": 1.0,
                "match_status": "match"
              },
              "Study Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Characteristics": {
                "ground_truth": "Statin switch, rosuvastatin",
                "prediction": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of ABCG2 c.421C/A or A/A vs c.421C/C, dose-adjusted Cox model",
                "score": 0.9077550172805786,
                "match_status": "partial_match"
              },
              "Characteristics Type": {
                "ground_truth": "Study Cohort",
                "prediction": "Study Cohort",
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Cases": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "Allele Of Frequency In Controls": {
                "ground_truth": null,
                "prediction": null,
                "score": 1.0,
                "match_status": "match"
              },
              "P Value": {
                "ground_truth": "= 0.660",
                "prediction": "= 0.660",
                "score": 1.0,
                "match_status": "match"
              },
              "Ratio Stat Type": {
                "ground_truth": "Unknown",
                "prediction": "HR",
                "score": 0.0,
                "match_status": "no_match"
              },
              "Ratio Stat": {
                "ground_truth": null,
                "prediction": 0.81,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Start": {
                "ground_truth": null,
                "prediction": 0.31,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Confidence Interval Stop": {
                "ground_truth": null,
                "prediction": 2.1,
                "score": 0.0,
                "match_status": "no_match"
              },
              "Biogeographical Groups": {
                "ground_truth": "European",
                "prediction": "European",
                "score": 1.0,
                "match_status": "match"
              }
            }
          }
        ]
      },
      "extra_predictions": {
        "count": 41,
        "items": [
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 1,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521T/C vs c.521T/T, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.640",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.94,
              "Confidence Interval Start": 0.7,
              "Confidence Interval Stop": 1.24,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 3,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of SLCO1B1 c.521T/C vs c.521T/T, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.226",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.75,
              "Confidence Interval Start": 0.71,
              "Confidence Interval Stop": 4.31,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 5,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch vs no switch; comparison of simvastatin 20 mg vs 10 mg, dose term in Cox model (not pharmacogenetic)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.498",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.13,
              "Confidence Interval Start": 0.8,
              "Confidence Interval Stop": 1.6,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 6,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch vs no switch; comparison of simvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (not pharmacogenetic)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.035",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.48,
              "Confidence Interval Start": 1.03,
              "Confidence Interval Stop": 2.12,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 7,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of simvastatin 20 mg vs 10 mg, dose term in Cox model",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.284",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 2.0,
              "Confidence Interval Start": 0.56,
              "Confidence Interval Stop": 7.14,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 8,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 916,
              "Study Controls": null,
              "Characteristics": "Finnish simvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of simvastatin 40 or 80 mg vs 10 mg, dose term in Cox model",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.379",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.84,
              "Confidence Interval Start": 0.47,
              "Confidence Interval Stop": 7.12,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 9,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of SLCO1B1 c.521T/C vs c.521T/T, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.339",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.82,
              "Confidence Interval Start": 0.55,
              "Confidence Interval Stop": 1.23,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 11,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of SLCO1B1 c.521T/C vs c.521T/T, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.667",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.25,
              "Confidence Interval Start": 0.46,
              "Confidence Interval Stop": 3.38,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 12,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of SLCO1B1 c.521C/C vs c.521T/T, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.799",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.3,
              "Confidence Interval Start": 0.17,
              "Confidence Interval Stop": 10.1,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 14,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of ABCG2 c.421C/A or A/A vs c.421C/C, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.706",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.27,
              "Confidence Interval Start": 0.37,
              "Confidence Interval Stop": 4.39,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 15,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of combined 2\u20134 SLCO1B1/ABCG2 risk alleles vs 0\u20131 alleles, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.843",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.94,
              "Confidence Interval Start": 0.51,
              "Confidence Interval Stop": 1.74,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 16,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of combined 2\u20134 SLCO1B1/ABCG2 risk alleles vs 0\u20131 alleles, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.600",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.58,
              "Confidence Interval Start": 0.08,
              "Confidence Interval Stop": 4.39,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 17,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.463",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.86,
              "Confidence Interval Start": 0.58,
              "Confidence Interval Stop": 1.28,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 18,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.907",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.03,
              "Confidence Interval Start": 0.65,
              "Confidence Interval Stop": 1.62,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 19,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.745",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.85,
              "Confidence Interval Start": 0.32,
              "Confidence Interval Stop": 2.24,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 20,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.151",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.22,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 1.73,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 21,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.428",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.85,
              "Confidence Interval Start": 0.57,
              "Confidence Interval Stop": 1.27,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 22,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.955",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.01,
              "Confidence Interval Start": 0.64,
              "Confidence Interval Stop": 1.6,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 23,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.759",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.86,
              "Confidence Interval Start": 0.33,
              "Confidence Interval Stop": 2.26,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 24,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.154",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.22,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 1.75,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 25,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.430",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.85,
              "Confidence Interval Start": 0.57,
              "Confidence Interval Stop": 1.27,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 26,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch vs no switch; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.949",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.02,
              "Confidence Interval Start": 0.64,
              "Confidence Interval Stop": 1.6,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 27,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 20 mg vs 10 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.762",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.86,
              "Confidence Interval Start": 0.33,
              "Confidence Interval Stop": 2.27,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 28,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 780,
              "Study Controls": null,
              "Characteristics": "Finnish atorvastatin initiators; outcome: statin switch plus temporally associated CK measurement vs no such event; comparison of atorvastatin 40 or 80 mg vs 10 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.157",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.23,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 1.77,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 31,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of combined 2\u20134 SLCO1B1/ABCG2 risk alleles vs 0\u20131 alleles, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.149",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.23,
              "Confidence Interval Start": 0.03,
              "Confidence Interval Stop": 1.69,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 32,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 10 mg vs 5 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.038",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 3.55,
              "Confidence Interval Start": 1.07,
              "Confidence Interval Stop": 11.8,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 33,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 20 or 40 mg vs 5 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.681",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.45,
              "Confidence Interval Start": 0.24,
              "Confidence Interval Stop": 8.78,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 34,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 10 mg vs 5 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.038",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 3.56,
              "Confidence Interval Start": 1.07,
              "Confidence Interval Stop": 11.8,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 35,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 20 or 40 mg vs 5 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.644",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.53,
              "Confidence Interval Start": 0.25,
              "Confidence Interval Stop": 9.34,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 36,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 10 mg vs 5 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.036",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 3.61,
              "Confidence Interval Start": 1.09,
              "Confidence Interval Stop": 12.0,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 37,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 184,
              "Study Controls": null,
              "Characteristics": "Finnish rosuvastatin initiators; outcome: statin switch vs no switch; comparison of rosuvastatin 20 or 40 mg vs 5 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.700",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.43,
              "Confidence Interval Start": 0.23,
              "Confidence Interval Stop": 8.68,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 41,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of combined 2\u20134 SLCO1B1/ABCG2/CYP2C9 risk alleles vs 0\u20131 alleles, dose-adjusted Cox model",
              "Characteristics Type": "Study Cohort",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.094",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.88,
              "Confidence Interval Start": 0.9,
              "Confidence Interval Stop": 3.96,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 42,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 40 mg vs 20 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.868",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.91,
              "Confidence Interval Start": 0.31,
              "Confidence Interval Stop": 2.73,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 43,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 80 mg vs 20 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.303",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.62,
              "Confidence Interval Start": 0.65,
              "Confidence Interval Stop": 4.05,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 44,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 40 mg vs 20 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.825",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.88,
              "Confidence Interval Start": 0.3,
              "Confidence Interval Stop": 2.64,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 45,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 80 mg vs 20 mg, dose term in Cox model (ABCG2 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.466",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.39,
              "Confidence Interval Start": 0.58,
              "Confidence Interval Stop": 3.34,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 46,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 40 mg vs 20 mg, dose term in Cox model (CYP2C9 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.832",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.89,
              "Confidence Interval Start": 0.3,
              "Confidence Interval Stop": 2.65,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 47,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 80 mg vs 20 mg, dose term in Cox model (CYP2C9 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.465",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.39,
              "Confidence Interval Start": 0.58,
              "Confidence Interval Stop": 3.34,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 48,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 40 mg vs 20 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.928",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 0.95,
              "Confidence Interval Start": 0.32,
              "Confidence Interval Stop": 2.85,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 49,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 70,
              "Study Controls": null,
              "Characteristics": "Finnish fluvastatin initiators; outcome: statin switch vs no switch; comparison of fluvastatin 80 mg vs 20 mg, dose term in Cox model (combined risk alleles block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.273",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.65,
              "Confidence Interval Start": 0.67,
              "Confidence Interval Stop": 4.04,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          },
          {
            "variant": "N/A",
            "gene": "N/A",
            "drug": "N/A",
            "annotation": {
              "Study Parameters ID": 51,
              "Variant Annotation ID": null,
              "Study Type": "cohort",
              "Study Cases": 92,
              "Study Controls": null,
              "Characteristics": "Finnish pravastatin initiators; outcome: statin switch vs no switch; comparison of pravastatin 40 mg vs 20 mg, dose term in Cox model (SLCO1B1 block)",
              "Characteristics Type": "drug",
              "Frequency In Cases": null,
              "Allele Of Frequency In Cases": null,
              "Frequency In Controls": null,
              "Allele Of Frequency In Controls": null,
              "P Value": "= 0.376",
              "Ratio Stat Type": "HR",
              "Ratio Stat": 1.43,
              "Confidence Interval Start": 0.65,
              "Confidence Interval Stop": 3.17,
              "Biogeographical Groups": "European",
              "Variant Annotation ID_norm": null
            }
          }
        ]
      }
    }
  }
}